ATTACHMENT A

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-41. (Canceled)

42. (Previously presented) A method of obtaining a purified human donor immunoglobulin composition comprising an antibody titer to an *S. aureus* serine-aspartate repeat (Sdr) protein in combination with an antibody titer to an *S. epidermidis* serine-asparate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors, said method comprising obtaining blood or plasma samples from human donors, screening said samples so as to select those samples having an antibody titer to an *S. aureus* Sdr protein and an antibody titer an *S. epidermidis* Sdr protein that are both in an amount that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma from the selected high-titer donors, and treating the donor blood plasma to obtain immunoglobulin in a purified state having an antibody titer to an *S. aureus* Sdr protein and an antibody titer to an *S. epidermidis* Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.

43. (Previously presented) The method of claim 42 wherein the *S. aureus* Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.

44. (Previously presented) The method of claim 42 wherein the *S. epidermidis* Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.

45. (Previously presented) The method of claim 42 wherein the resulting composition has an antibody titer to an S. aureus Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtain from unselected donors.

46. (Previously presented) The method of claim 42 wherein the resulting composition has a total antibody titer to an S. aureus Sdr protein that is greater than 0.2 Units/mg/IgG.

47. (Previously presented) The method according to claim 42 wherein donors having a high titer to a staphylococcal Sdr protein are determined by identifying those samples having a high titer of antibodies to the A domain of the staphylococcal Sdr protein.

48. (Previously presented) A method of obtaining a purified human donor immunoglobulin composition comprising an antibody titer to an *S. aureus* serine-aspartate repeat (Sdr) protein in combination with an antibody titer to an *S. epidermidis* serine-asparate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors, said method comprising administering an *S. aureus* Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the *S. aureus* Sdr protein that is higher that found in pooled intravenous immunoglobulin obtained from unselected donors, and administering an *S. epidermidis* Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the *S. epidermidis* Sdr protein that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma samples from the induced donors, and treating the donor blood or plasma to obtain immunoglobulin in a purified state having antibody titer to an *S. aureus* Sdr protein and an antibody titer to an *S. epidermidis* Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.

49. (Previously presented) The method of claim 48 wherein the *S. aureus* Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.

50. (Previously presented) The method of claim 48 wherein the *S. epidermidis* Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.

51. (Previously presented) The method of claim 48 wherein the resulting composition has an antibody titer to an *S. aureus* Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtain from unselected donors.

52. (Previously presented) The method of claim 48 wherein the resulting composition has a total antibody titer to an *S. aureus* Sdr protein that is greater than 0.2 Units/mg/IgG.

53. (Previously presented) The method of claim 48 wherein the Sdr protein administered to a human host donor is the A domain of the staphylococcal Sdr protein.

54-56. (Canceled).